APA (7th ed.) Citation
(2026). In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses. Molecular Oncology.
Chicago Style (17th ed.) Citation
"In Vitro and in Silico Modelling of ROS1‐positive Non‐small Cell Lung Cancer Reveals Fusion‐dependent Tyrosine Kinase Inhibitor Responses." Molecular Oncology 2026.
MLA (9th ed.) Citation
"In Vitro and in Silico Modelling of ROS1‐positive Non‐small Cell Lung Cancer Reveals Fusion‐dependent Tyrosine Kinase Inhibitor Responses." Molecular Oncology, 2026.
Warning: These citations may not always be 100% accurate.